Alcoholism: Developing Drugs for Treatment February 2015
Not for implementation. Contains non-binding recommendations.
- Docket Number:
- Issued by:
Guidance Issuing OfficeCenter for Drug Evaluation and Research
The purpose of this guidance is to assist sponsors in the clinical development of drugs for the 20 treatment of alcoholism. There are many different terms, definitions, and diagnostic criteria that 21 have been used to describe this condition. However, in this guidance, we use the term 22 alcoholism to describe patients with alcohol use problems that would make them candidates for 23 treatment with medication. As the World Health Organization (WHO) notes,3 alcoholism is a 24 “term of long-standing use” and is “generally taken to refer to chronic continual drinking or 25 periodic consumption of alcohol which is characterized by impaired control over drinking, 26 frequent episodes of intoxication, and preoccupation with alcohol and the use of alcohol despite 27 adverse consequences.”
You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All written comments should be identified with this document's docket number: FDA-2015-D-0152.